Literature DB >> 9831133

Recognition of a novel naturally processed, A2 restricted, HCV-NS4 epitope triggers IFN-gamma release in absence of detectable cytopathicity.

J Alexander1, M F Del Guercio, J D Fikes, R W Chesnut, F V Chisari, K M Chang, E Appella, A Sette.   

Abstract

Using short term CTL lines derived from HLA A2/Kb transgenic mice and IFN-gamma release assays we demonstrate that the NS4.1769 epitope, is generated from natural processing of the NS4 antigen, and presented in the context of the A2/Kb molecules. Interestingly, T cell recognition of the naturally processed form of the NS4. 1769 epitope was associated with significant IFN-gamma release, but no direct cytolytic activity. Epitopes of this phenotype might be of interest, in terms of therapy of chronic HCV infection by associating the benefit of localized lymphokine release with low or absent direct cytopathicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9831133     DOI: 10.1016/s0198-8859(98)00080-9

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  5 in total

1.  Identification of the epitopes on HCV core protein recognized by HLA-A2 restricted cytotoxic T lymphocytes.

Authors:  H C Zhou; D Z Xu; X P Wang; J X Zhang; Y Huang; Y P Yan; Y Zhu; B Q Jin
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  The design and implementation of the immune epitope database and analysis resource.

Authors:  Bjoern Peters; John Sidney; Phil Bourne; Huynh-Hoa Bui; Soeren Buus; Grace Doh; Ward Fleri; Mitch Kronenberg; Ralph Kubo; Ole Lund; David Nemazee; Julia V Ponomarenko; Muthu Sathiamurthy; Stephen P Schoenberger; Scott Stewart; Pamela Surko; Scott Way; Steve Wilson; Alessandro Sette
Journal:  Immunogenetics       Date:  2005-05-14       Impact factor: 2.846

3.  Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development.

Authors:  Karim M Abdel-Hady; Andres H Gutierrez; Frances Terry; Joe Desrosiers; Anne S De Groot; Hassan M E Azzazy
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model.

Authors:  T Arichi; T Saito; M E Major; I M Belyakov; M Shirai; V H Engelhard; S M Feinstone; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

Review 5.  Cellular immune responses against hepatitis C virus: the evidence base 2002.

Authors:  S Ward; G Lauer; R Isba; B Walker; P Klenerman
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.